The utility of cells as vehicles for oncolytic virus therapies

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Oncolytic viruses are emerging as promising anticancer agents, but efficient delivery and dispersal at sites of tumor growth remain a significant challenge. Viruses can be efficiently neutralized by antiviral antibodies in the blood stream or sequestered by phagocytic cells in the liver and spleen, and they often fail to extravasate and migrate in tumor deposits or in the tissues to which tumors metastasize. As an alternative to the administration of naked viruses, virus-infected carrier cells are currently under investigation as vehicles to deliver oncolytic viruses more reliably, uniformly and efficiently to sites of tumor growth in the body, even in virus-immune individuals. Aside from their virus chaperoning capabilities, certain carrier cell types may exert additional antitumor activities that operate in synergy with the oncolytic virus infection to mediate tumor regression.

Original languageEnglish (US)
Pages (from-to)380-386
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Issue number4
StatePublished - Aug 2008


  • Cell carrier
  • Oncolytic virus
  • Pre-existing immunity

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)


Dive into the research topics of 'The utility of cells as vehicles for oncolytic virus therapies'. Together they form a unique fingerprint.

Cite this